Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Chemoradiotherapy followed by surgery could improve the efficacy of treatments in patients with resectable esophageal carcinoma.

Wang F, Wang YM, He W, Li XK, Peng FH, Yang XL, Fan QX.

Chin Med J (Engl). 2013 Aug;126(16):3138-45.

2.

Meta-analysis of postoperative efficacy in patients receiving chemoradiotherapy followed by surgery for resectable esophageal carcinoma.

Deng J, Wang C, Xiang M, Liu F, Liu Y, Zhao K.

Diagn Pathol. 2014 Jul 16;9:151. doi: 10.1186/1746-1596-9-151.

3.

Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.

Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J Jr, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):427-36.

PMID:
15380576
4.

Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis.

Malthaner RA, Wong RK, Rumble RB, Zuraw L; Members of the Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.

BMC Med. 2004 Sep 24;2:35. Review.

5.

Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis.

Jin HL, Zhu H, Ling TS, Zhang HJ, Shi RH.

World J Gastroenterol. 2009 Dec 21;15(47):5983-91.

6.

Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma.

Lv J, Cao XF, Zhu B, Ji L, Tao L, Wang DD.

World J Gastroenterol. 2009 Oct 21;15(39):4962-8. Review.

7.

Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: a meta-analysis.

Wang DB, Zhang X, Han HL, Xu YJ, Sun DQ, Shi ZL.

Dig Dis Sci. 2012 Dec;57(12):3226-33. doi: 10.1007/s10620-012-2263-8. Epub 2012 Jun 14.

PMID:
22695886
10.

Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.

Koo DH, Park SI, Kim YH, Kim JH, Jung HY, Lee GH, Choi KD, Song HJ, Song HY, Shin JH, Cho KJ, Yoon DH, Kim SB.

Cancer Chemother Pharmacol. 2012 Mar;69(3):655-63. doi: 10.1007/s00280-011-1750-5. Epub 2011 Oct 4.

PMID:
21968953
11.

Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS).

van Heijl M, van Lanschot JJ, Koppert LB, van Berge Henegouwen MI, Muller K, Steyerberg EW, van Dekken H, Wijnhoven BP, Tilanus HW, Richel DJ, Busch OR, Bartelsman JF, Koning CC, Offerhaus GJ, van der Gaast A.

BMC Surg. 2008 Nov 26;8:21. doi: 10.1186/1471-2482-8-21.

12.

The effectiveness of planned esophagectomy after neoadjuvant chemoradiotherapy for advanced esophageal carcinomas.

Kato H, Fukuchi M, Manda R, Faried A, Takita J, Nakajima M, Miyazaki T, Sohda M, Fukai Y, Masuda N, Tsukada K, Kuwano H.

Anticancer Res. 2004 Nov-Dec;24(6):4091-6.

13.

Preoperative chemotherapy for resectable thoracic esophageal cancer.

Malthaner R, Fenlon D.

Cochrane Database Syst Rev. 2003;(4):CD001556. Review. Update in: Cochrane Database Syst Rev. 2006;(3):CD001556.

PMID:
14583936
14.

Preoperative chemotherapy for resectable thoracic esophageal cancer.

Malthaner R, Fenlon D.

Cochrane Database Syst Rev. 2001;(1):CD001556. Review. Update in: Cochrane Database Syst Rev. 2003;(4):CD001556.

PMID:
11279723
15.

Preoperative chemoradiotherapy for esophageal or junctional cancer.

van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group.

N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088.

16.

A single institutional non-randomized retrospective comparison between definitive chemoradiotherapy and radical surgery in 82 Japanese patients with resectable esophageal squamous cell carcinoma.

Yamashita H, Nakagawa K, Yamada K, Kaminishi M, Mafune K, Ohtomo K.

Dis Esophagus. 2008;21(5):430-6. doi: 10.1111/j.1442-2050.2007.00793.x.

PMID:
19125797
17.

Neoadjuvant chemotherapy for resectable esophageal carcinoma: a meta-analysis of randomized clinical trials.

Xu XH, Peng XH, Yu P, Xu XY, Cai EH, Guo P, Li K.

Asian Pac J Cancer Prev. 2012;13(1):103-10.

18.

Clinical study of concurrent chemoradiotherapy or radiotherapy alone for esophageal cancer patients with positive lymph node metastasis.

Han J, Zhu W, Yu C, Zhou X, Li T, Zhang X.

Tumori. 2012 Jan-Feb;98(1):60-5. doi: 10.1700/1053.11501.

PMID:
22495703
19.

[A multi-centered randomized controlled study of neo-adjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of esophagus: an interim analysis].

YANG H, FU JH, LIU MZ, FANG WT, WANG JM, CHEN YP, CHEN ZJ, XIANG JQ, YANG HJ, MAO WM, ZHENG X, ZHU CC, KONG M, HAN YT, LI T.

Zhonghua Yi Xue Za Zhi. 2012 Apr 17;92(15):1028-32. Chinese.

PMID:
22781642
20.

Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.

Hsu FM, Lee JM, Huang PM, Lin CC, Hsu CH, Tsai YC, Lee YC, Chia-Hsien Cheng J.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e593-9. doi: 10.1016/j.ijrobp.2011.04.032. Epub 2011 Jun 12.

PMID:
21658851
Items per page

Supplemental Content

Write to the Help Desk